Osteopontin: an emerging therapeutic target for anticancer therapy

Bibliography

• RANGASWAMI H, BULBULE A, KUNDU GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. (2006) 16(2):79-87.
   PubMed Web of Science ®Google Scholar
• FISHER LW, FEDARKO NS: Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect. Tissue Res. (2003) 44(Suppl. 1):33-40.
   PubMed Web of Science ®Google Scholar
• RITTLING SR, CHAMBERS AF: Role of osteopontin in tumour progression. Br. J. Cancer (2004) 90(10):1877-1881.
   PubMed Web of Science ®Google Scholar
• WAI PY, KUO PC: The role of osteopontin in tumor metastasis. J. Surg. Res. (2004) 121(2):228-241.
   PubMed Web of Science ®Google Scholar
• CHAKRABORTY G, JAIN S, BEHERA R et al.: The multifaceted role of osteopontin in cell signaling, tumor progression and angiogenesis. Curr. Mol. Med. (2006) 6(8):819-830.
   PubMed Web of Science ®Google Scholar
• SODEK J, GANSS B, MCKEE MD: Osteopontin. Crit. Rev. Oral. Biol. Med. (2000) 11(3):279-303.
   PubMedGoogle Scholar
• DENHARDT DT, GUO X: Osteopontin: a protein with diverse functions. FASEB J. (1993) 7(15):1475-1482.
   PubMed Web of Science ®Google Scholar
• JOHNSON GA, BURGHARDT RC, BAZER FW, SPENCER TE: Osteopontin: roles in implantation and placentation. Biol. Reprod. (2003) 69(5):1458-1471.
   PubMed Web of Science ®Google Scholar
• PANDA D, KUNDU GC, LEE BI et al.: Potential roles of osteopontin and αVβ3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. USA (1997) 94(17):9308-9313.
   PubMed Web of Science ®Google Scholar
• CHAMBERS AF, MACDONALD IC, SCHMIDT EE, MORRIS VL, GROOM AC: Clinical targets for anti-metastasis therapy. Adv. Cancer Res. (2000) 79:91-121.
   PubMed Web of Science ®Google Scholar
• HEDLEY BD, WINQUIST E, CHAMBERS AF: Therapeutic targets for antimetastatic therapy. Expert Opin. Ther. Targets (2004) 8(6):527-536.
   Web of Science ®Google Scholar
• FOLKMAN J: Fighting cancer by attacking its blood supply. Sci. Am. (1996) 275(3):150-154.
   PubMed Web of Science ®Google Scholar
• GASPARINI G, LONGO R, TOI M, FERRARA N: Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. (2005) 2(11):562-577.
   PubMedGoogle Scholar
• SENGER DR, WIRTH DF, HYNES RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell (1979) 16(4):885-893.
   PubMed Web of Science ®Google Scholar
• PRINCE CW, OOSAWA T, BUTLER WT et al.: Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J. Biol. Chem. (1987) 262(6):2900-2907.
   PubMed Web of Science ®Google Scholar
• FURGER KA, MENON RK, TUCK AB, BRAMWELL VH, CHAMBERS AF: The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. (2001) 1(5):621-632.
   PubMedGoogle Scholar
• SHIMAOKA M, SPRINGER TA: Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov. (2003) 2(9):703-716.
   PubMed Web of Science ®Google Scholar
• WEBER GF: The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta. (2001) 1552(2):61-85.
   PubMed Web of Science ®Google Scholar
• HORTON MA: The αVβ3 integrin ‘vitronectin receptor’. Int. J. Biochem. Cell Biol. (1997) 29(5):721-725.
   PubMed Web of Science ®Google Scholar
• GOODISON S, URQUIDI V, TARIN D: CD44 cell adhesion molecules. Mol. Pathol. (1999) 52(4):189-196.
   PubMedGoogle Scholar
• NAOR D, SIONOV RV, ISH-SHALOM D: CD44: structure, function, and association with the malignant process. Adv. Cancer Res. (1997) 71:241-319.
   PubMed Web of Science ®Google Scholar
• KATAGIRI YU, SLEEMAN J, FUJII H et al.: CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. (1999) 59(1):219-226.
   PubMed Web of Science ®Google Scholar
• MARROQUIN CE, DOWNEY L, GUO H, KUO PC: Osteopontin increases CD44 expression and cell adhesion in RAW 264.7 murine leukemia cells. Immunol. Lett. (2004) 95(1):109-112.
   Google Scholar
• TAKAHASHI K, TAKAHASHI F, HIRAMA M, TANABE KK, FUKUCHI Y: Restoration of CD44s in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity. Lung Cancer (2003) 41(2):145-153.
   Google Scholar
• GAO C, GUO H, DOWNEY L, MARROQUIN C, WEI J, KUO PC: Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis (2003) 24(12):1871-1878.
   PubMed Web of Science ®Google Scholar
• KHAN SA, COOK AC, KAPPIL M et al.: Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin. Exp. Metastasis (2005) 22(8):663-673.
   Google Scholar
• CHELLAIAH M, FITZGERALD C, FILARDO EJ, CHERESH DA, HRUSKA KA: Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha V-subunit. Endocrinology (1996) 137(6):2432-2440.
   PubMedGoogle Scholar
• AL-SHAMI R, SORENSEN ES, EK-RYLANDER B, ANDERSSON G, CARSON DD, FARACH-CARSON MC: Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 S6 kinase-dependent pathway. J. Cell. Biochem. (2005) 94(6):1218-1233.
   Google Scholar
• DAS R, MAHABELESHWAR GH, KUNDU GC: Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem. (2003) 278(31):28593-28606.
   PubMedGoogle Scholar
• TUCK AB, HOTA C, WILSON SM, CHAMBERS AF: Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene (2003) 22(8):1198-1205.
   PubMed Web of Science ®Google Scholar
• DAS R, MAHABELESHWAR GH, KUNDU GC: Osteopontin induces AP-1- mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J. Biol. Chem. (2004) 279(12):11051-11064.
   PubMed Web of Science ®Google Scholar
• FINGLETON B: Matrix metalloproteinases: roles in cancer and metastasis. Front. Biosci. (2006) 11:479-491.
   PubMedGoogle Scholar
• DAVIDSON B, REICH R, RISBERG B, NESLAND JM: The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh. Patol. (2002) 64(3):47-53.
   PubMedGoogle Scholar
• DUFFY MJ: The urokinase plasminogen activator system: role in malignancy. Curr. Pharm. Des. (2004) 10(1):39-49.
   PubMed Web of Science ®Google Scholar
• DANO K, BEHRENDT N, HOYER-HANSEN G et al.: Plasminogen activation and cancer. Thromb. Haemost. (2005) 93(4):676-681.
   PubMed Web of Science ®Google Scholar
• PHILIP S, BULBULE A, KUNDU GC: Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane Type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. (2001) 276(48):44926-44935.
   PubMed Web of Science ®Google Scholar
• PHILIP S, KUNDU GC: Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J. Biol. Chem. (2003) 278(16):14487-14497.
   PubMed Web of Science ®Google Scholar
• MI Z, GUO H, WAI PY, GAO C, KUO PC: Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis (2006) 27(6):1134-1145.
   PubMed Web of Science ®Google Scholar
• RANGASWAMI H, BULBULE A, KUNDU GC: Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IκBα kinase-dependent nuclear factor κB-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem. (2004) 279(37):38921-38935.
   PubMed Web of Science ®Google Scholar
• RANGASWAMI H, BULBULE A, KUNDU GC: JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrixmetalloproteinase-9 activation. J. Biol. Chem. (2005) 280(19):19381-19392.
   Google Scholar
• JAIN S, CHAKRABORTY G, KUNDU GC: The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res. (2006) 66(13):6638-6648.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, MONTGOMERY AM, ROSENFELD M et al.: Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79(7):1157-1164.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, CLARK RA, CHERESH DA: Requirement of vascular integrin αVβ3 for angiogenesis. Science (1994) 264(5158):569-571.
   PubMed Web of Science ®Google Scholar
• SCATENA M, ALMEIDA M, CHAISSON ML, FAUSTO N, NICOSIA RF, GIACHELLI CM: NF-kappaB mediates αVβ3 integrin-induced endothelial cell survival. J. Cell. Biol. (1998) 141(4):1083-1093.
   PubMed Web of Science ®Google Scholar
• PRITZKER LB, SCATENA M, GIACHELLI CM: The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol. Biol. Cell. (2004) 15(6):2834-2841.
   PubMed Web of Science ®Google Scholar
• KHAN SA, LOPEZ-CHUA CA, ZHANG J, FISHER LW, SORENSEN ES, DENHARDT DT: Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J. Cell. Biochem. (2002) 85(4):728-736.
   PubMed Web of Science ®Google Scholar
• SENGER DR, LEDBETTER SR, CLAFFEY KP, PAPADOPOULOS-SERGIOU A, PERUZZI CA, DETMAR M: Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the αVβ3 integrin, osteopontin, and thrombin. Am. J. Pathol. (1996) 149(1):293-305.
   PubMed Web of Science ®Google Scholar
• SHIJUBO N, UEDE T, KON S et al.: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med. (1999) 160(4):1269-1273.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI F, AKUTAGAWA S, FUKUMOTO H et al.: Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int. J. Cancer (2002) 98(5):707-712.
   Google Scholar
• TUCK AB, CHAMBERS AF: The role of osteopontin in breast cancer: clinical and experimental studies. J. Mammary Gland Biol. Neoplasia (2001) 6(4):419-429.
   PubMed Web of Science ®Google Scholar
• CARLINFANTE G, VASSILIOU D, SVENSSON O, WENDEL M, HEINEGARD D, ANDERSSON G: Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin. Exp. Metastasis (2003) 20(5):437-444.
   Google Scholar
• FEDARKO NS, JAIN A, KARADAG A, VAN EMAN MR, FISHER LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res. (2001) 7(12):4060-4066.
   PubMed Web of Science ®Google Scholar
• FOROOTAN SS, FOSTER CS, AACHI VR et al.: Prognostic significance of osteopontin expression in human prostate cancer. Int. J. Cancer (2006) 118(9):2255-2261.
   PubMed Web of Science ®Google Scholar
• AGRAWAL D, CHEN T, IRBY R et al.: Osteopontin identified as colon cancer tumor progression marker. C. R. Biol. (2003) 326(10-11):1041-1043.
   Google Scholar
• IRBY RB, MCCARTHY SM, YEATMAN TJ: Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin. Exp. Metastasis (2004) 21(6):515-523.
   Google Scholar
• AGRAWAL D, CHEN T, IRBY R et al.: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl. Cancer Inst. (2002) 94(7):513-521.
   PubMed Web of Science ®Google Scholar
• ZHOU Y, DAI DL, MARTINKA M et al.: Osteopontin expression correlates with melanoma invasion. J. Invest. Dermatol. (2005) 124(5):1044-1052.
   PubMedGoogle Scholar
• BOLDRINI L, DONATI V, DELL’OMODARME M et al.: Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br. J. Cancer (2005) 93(4):453-457.
   PubMed Web of Science ®Google Scholar
• KAO CL, CHIOU SH, HO DM et al.: Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor. Am. J. Clin. Pathol. (2005) 123(2):297-304.
   Google Scholar
• WONG TS, KWONG DL, SHAM J, WEI WI, KWONG YL, YUEN AP: Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur. J. Surg. Oncol. (2005) 31(5):555-558.
   Google Scholar
• DING L, ZHENG S: Expression and clinical significance of osteopontin in colorectal cancer and liver metastatic tissues. Zhonghua Wai Ke Za Zhi (2002) 40(10):773-775.
   Google Scholar
• UE T, YOKOZAKI H, KITADAI Y et al.: Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer. (1998) 79(2):127-132.
   PubMed Web of Science ®Google Scholar
• WONG YF, CHEUNG TH, TSAO GS et al.: Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. Int. J. Cancer (2006) 118(10):2461-2469.
   PubMedGoogle Scholar
• HAYLOCK DN, NILSSON SK: Osteopontin: a bridge between bone and blood. Br. J. Haematol. (2006) (In Press).
   Google Scholar
• HE B, MIRZA M, WEBER GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene (2006) 25(15):2192-2202.
   PubMed Web of Science ®Google Scholar
• JEN KY, GEWIRTZ AM: Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies. Stem Cells (2000) 8(5):307-319
   Google Scholar
• SCANLON KJ, OHTA Y, ISHIDA H et al.: Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J. (1995) 9(13):1288-1296.
   PubMed Web of Science ®Google Scholar
• GARDNER HA, BERSE B, SENGER DR: Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene (1994) 9(8):2321-2326.
   PubMedGoogle Scholar
• SU L, MUKHERJEE AB, MUKHERJEE BB: Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene (1995) 10(11):2163-2169.
   PubMedGoogle Scholar
• ADWAN H, BAUERLE TJ, BERGER MR: Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther. (2004) 11(2):109-120.
   PubMed Web of Science ®Google Scholar
• ADWAN H, BAUERLE T, NAJAJREH Y, ELAZER V, GOLOMB G, BERGER MR: Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int. J. Oncol. (2004) 24(5):1235-1244.
   Google Scholar
• TONG AW, ZHANG YA, NEMUNAITIS J: Small interfering RNA for experimental cancer therapy. Curr. Opin. Mol. Ther. (2005) 7(2):114-124.
   PubMed Web of Science ®Google Scholar
• TAKEI Y, KADOMATSU K, YUZAWA Y, MATSUO S, MURAMATSU T: A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. (2004) 64(10):3365-3370.
   PubMed Web of Science ®Google Scholar
• KANG CS, ZHANG ZY, JIA ZF et al.: Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther. (2006) 13(5):530-538.
   PubMed Web of Science ®Google Scholar
• PU P, LIU X, LIU A, CUI J, ZHANG Y: Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo. J. Neurosurg. (2000) 92(1):132-139.
   Google Scholar
• NIU XY, PENG ZL, DUAN WQ, WANG H, WANG P: Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int. J. Gynecol. Cancer (2006) 16(2):743-751.
   PubMed Web of Science ®Google Scholar
• AIT-SI-ALI S, GUASCONI V, HAREL-BELLAN A: RNA interference and its possible use in cancer therapy. Bull. Cancer (2004) 91(1):15-18.
   Google Scholar
• OHYAMA Y, NEMOTO H, RITTLING S et al.: Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. J. Bone. Miner. Res. (2004) 19(10):1706-1711.
   PubMed Web of Science ®Google Scholar
• NEMOTO H, RITTLING SR, YOSHITAKE H et al.: Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J. Bone. Miner. Res. (2001) 16(4):652-659.
   Google Scholar
• TERAMOTO H, CASTELLONE MD, MALEK RL et al.: Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene (2005) 24(3):489-501.
   PubMed Web of Science ®Google Scholar
• KOLB A, KLEEFF J, GUWEIDHI A et al.: Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol. Ther. (2005) 4(7):740-746.
   PubMed Web of Science ®Google Scholar
• ITO T, HASHIMOTO Y, TANAKA E et al.: An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin. Cancer Res. (2006) 12(4):1308-1316.
   PubMed Web of Science ®Google Scholar
• WAI PY, MI Z, GUO H et al.: Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis (2005) 26(4):741-751.
   Google Scholar
• SHEVDE LA, SAMANT RS, PAIK JC et al.: Osteopontin knockdown suppresses tumourigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin. Exp. Metastasis (2006) (In Press).
   Google Scholar
• KON S, MAEDA M, SEGAWA T et al.: Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J. Cell. Biochem. (2000) 77(3):487-498.
   PubMedGoogle Scholar
• RITTLING SR, FENG F: Detection of mouse osteopontin by western blotting. Biochem. Biophys. Res. Commun. (1998) 250(2):287-292.
   Google Scholar
• THALMANN GN, SIKES RA, DEVOLL RE et al.: Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res. (1999) 5(8):2271-2277.
   PubMedGoogle Scholar
• BAUTISTA DS, XUAN JW, HOTA C, CHAMBERS AF, HARRIS JF: Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J. Biol. Chem. (1994) 269(37):23280-23285.
   PubMed Web of Science ®Google Scholar
• ABE M, HIURA K, WILDE J et al.: Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood (2004) 104(8):2484-2491.
   PubMed Web of Science ®Google Scholar
• YE QH, QIN LX, FORGUES M et al.: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. (2003) 9(4):416-423.
   PubMed Web of Science ®Google Scholar
• LECRONE V, LI W, DEVOLL RE, LOGOTHETIS C, FARACH-CARSON MC: Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. Cell Calcium (2000) 27(1):35-42.
   PubMed Web of Science ®Google Scholar
• HARMS JF, WELCH DR, SAMANT RS et al.: A small molecule antagonist of the αVβ3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin. Exp. Metastasis (2004) 21(2):119-128.
   PubMedGoogle Scholar